15th May 2020
Business as usual at Pure Drug Safety despite the continuing coronavirus pandemic

Business as usual at Pure Drug Safety

We just wanted to reach out to say hello and let you know that we’re thinking of you as we enter another phase of change due […]
8th April 2020
Pharmaceutical Administration Services from PDS for Life Science companies

Admin support available for Life Science companies from Pure Drug Safety

When we launched our Pharmaceutical Administration Services back in January 2020, little did we realise how vital they would become to the efficient running of life […]
19th March 2020
GCP Inspections: Expectations and the dos and don’ts for hosting

GCP Inspections: Expectations and the dos and don’ts for hosting

Good Clinical Practice (GCP) inspections and how they are conducted has evolved massively over the years and has had to, due to the increased complexity of […]
13th March 2020
It's business as usual at PDS during the coronavirus / COVID-19 crisis

Coronavirus / COVID-19 – business as usual at PDS

We wanted to assure you that it’s business as usual here at PDS during the current coronavirus crisis. We are following the guidance offered by HM […]
13th March 2020
Advice for Management of Clinical trials in relation to Coronavirus

Advice for Management of Clinical trials in relation to Coronavirus

As we are all now terribly aware, COVID-19 is proving to be a challenge across all areas of industry. Recently, the MHRA have announced on their […]
17th February 2020
NICE agrees to look again at Novartis’ Aimovig for migraine prevention

Good news for severe migraine suffers everywhere as NICE agrees to look again at Novartis’ Aimovig for migraine prevention

The UK’s medicines cost-effectiveness agency NICE has agreed to look again at its decision to turn down NHS funding of Novartis’ Aimovig for migraine prevention after […]
12th February 2020
What happens after Brexit for Pharmacovigilance and Regulatory?

What happens after Brexit for Pharmacovigilance and Regulatory?

7th February 2020
Pharmacovigilance (QPPV) provision post-Brexit

Pharmacovigilance (QPPV) provision post-Brexit

There has been and still is a huge amount of confusion regarding the requirements for establishing a UK QPPV following the UK’s exit from Europe on […]
15th January 2020

Is your pharmaceutical company Brexit ready?

Pure Drug Safety is ready to help you with your post Brexit pharmacovigilance and regulatory requirements – deal or no deal. Just call us now for […]